S Bielfeldt1, D Wilhelm1, C Neumeister2, U Schwantes3, K-P Wilhelm1. 1. proDERM Institute for Applied Dermatological Research, Kiebitzweg 2, 22869, Schenefeld, Hamburg, Germany. 2. Dr. Pfleger Arzneimittel GmbH, Dr.-Robert-Pfleger-Str. 12, 96052, Bamberg, Germany. claudia.neumeister@dr-pfleger.de. 3. Dr. Pfleger Arzneimittel GmbH, Dr.-Robert-Pfleger-Str. 12, 96052, Bamberg, Germany.
Abstract
BACKGROUND: Xerostomia is associated with several diseases and is a side effect of certain drugs, resulting from reduced saliva secretion. Often, aged and sometimes younger people suffer from (idiopathic) xerostomia. Chewing gum and sucking pastilles may relieve symptoms of xerostomia by increasing the salivary flow rate due to the mechanical effect of sucking and gustatory stimulation. Swallowing problems and the urge to cough or experiencing a tickling sensation in the throat might be alleviated through a reduction in dry mouth symptoms. We investigated whether a pastille containing four polysaccharides increased the salivary flow rate and relieved the symptoms of dry mouth. METHODS:Participating subjects with xerostomia were randomized into two equally balanced treatment groups. Subjects received the pastille on Day 1 and a control product (Parafilm®) on Day 3, or vice versa. Unstimulated saliva was collected every 2.5 min for 0-10 min. Stimulated saliva was collected after subjects sucked the pastille or the control product. The salivary flow rate was determined gravimetrically, and, in parallel, the feeling of dry mouth was assessed using a visual analog scale. Saliva surface tension was measured in pooled saliva samples (0-5 min of sampling). Additionally, in stimulated saliva from six subjects who sucked the pastille, the presence of the main ingredient-gum arabic-was examined by Raman spectroscopy. RESULTS: Chewing the pastille significantly increased the mean salivary flow rate by 8.03 g/10 min compared to the mean changes after chewing the control product (+ 3.71 g/10 min; p < 0.0001). The mean score of dry mouth was significantly alleviated by the pastille (- 19.9 ± 17.9 mm) compared to the control product (- 3.3 ± 18.1 mm). No difference between the two products was seen regarding the saliva surface tension. Gum arabic was present in the saliva of all investigated subjects for up to 10 min after sucking the pastille. CONCLUSIONS: The pastille was well tolerated and effective in increasing the salivary flow rate and reducing mouth dryness after sucking. These results were in line with the detection of the main ingredient, gum arabic, in saliva for up to 10 min after sucking the pastille. Trial registration German Register Clinical Trials (Deutsches Register Klinische Studien, DRKS) DRKS-ID: DRKS00017393, Registered 29 May 2019, https://www.drks.de/drks_web/navigate.do?navigationId=trial . HTML&TRIAL_ID = DRKS00017393.
RCT Entities:
<span class="abstract_title">BACKGROUND: <span class="Disease">Xerostomia is associated with several diseases and is a side effect of certain drugs, resulting from reduced saliva secretion. Often, aged and sometimes younger people suffer from (idiopathic) xerostomia. Chewing gum and sucking pastilles may relieve symptoms of xerostomia by increasing the salivary flow rate due to the mechanical effect of sucking and gustatory stimulation. Swallowing problems and the urge to cough or experiencing a tickling sensation in the throat might be alleviated through a reduction in dry mouth symptoms. We investigated whether a pastille containing four polysaccharides increased the salivary flow rate and relieved the symptoms of dry mouth. METHODS: Participating subjects with xerostomia were randomized into two equally balanced treatment groups. Subjects received the pastille on Day 1 and a control product (Parafilm®) on Day 3, or vice versa. Unstimulated saliva was collected every 2.5 min for 0-10 min. Stimulated saliva was collected after subjects sucked the pastille or the control product. The salivary flow rate was determined gravimetrically, and, in parallel, the feeling of dry mouth was assessed using a visual analog scale. Saliva surface tension was measured in pooled saliva samples (0-5 min of sampling). Additionally, in stimulated saliva from six subjects who sucked the pastille, the presence of the main ingredient-gum arabic-was examined by Raman spectroscopy. RESULTS: Chewing the pastille significantly increased the mean salivary flow rate by 8.03 g/10 min compared to the mean changes after chewing the control product (+ 3.71 g/10 min; p < 0.0001). The mean score of dry mouth was significantly alleviated by the pastille (- 19.9 ± 17.9 mm) compared to the control product (- 3.3 ± 18.1 mm). No difference between the two products was seen regarding the saliva surface tension. Gum arabic was present in the saliva of all investigated subjects for up to 10 min after sucking the pastille. CONCLUSIONS: The pastille was well tolerated and effective in increasing the salivary flow rate and reducing mouth dryness after sucking. These results were in line with the detection of the main ingredient, gum arabic, in saliva for up to 10 min after sucking the pastille. Trial registration German Register Clinical Trials (Deutsches Register Klinische Studien, DRKS) DRKS-ID: DRKS00017393, Registered 29 May 2019, https://www.drks.de/drks_web/navigate.do?navigationId=trial . HTML&TRIAL_ID = DRKS00017393.
Entities:
Keywords:
Dry mouth; Medical device; Pastille; Raman spectroscopy of saliva; Saliva surface tension; Salivary flow rate; Xerostomia
Authors: Joanna Mystkowska; Halina Car; Jan Ryszard Dąbrowski; Justyna Romanowska; Marcin Klekotka; Anna Justyna Milewska Journal: Oral Health Prev Dent Date: 2018 Impact factor: 1.256
Authors: Patricia Del Vigna de Almeida; Ana Maria Trindade Grégio; Maria Angela Naval Machado; Antonio Adilson Soares de Lima; Luciana Reis Azevedo Journal: J Contemp Dent Pract Date: 2008-03-01
Authors: V N Kazakov; A A Udod; Iryna I Zinkovych; V B Fainerman; R Miller Journal: Colloids Surf B Biointerfaces Date: 2009-06-13 Impact factor: 5.268
Authors: Randi Angela Baus; Michael Franz Haug; Christina Leichner; Max Jelkmann; Andreas Bernkop-Schnürch Journal: Mol Pharm Date: 2019-04-30 Impact factor: 4.939
Authors: W Murray Thomson; Herenia P Lawrence; Jonathan M Broadbent; Richie Poulton Journal: Health Qual Life Outcomes Date: 2006-11-08 Impact factor: 3.186
Authors: Rosa María López-Pintor; Elisabeth Casañas; José González-Serrano; Julia Serrano; Lucía Ramírez; Lorenzo de Arriba; Gonzalo Hernández Journal: J Diabetes Res Date: 2016-07-10 Impact factor: 4.011